We could not find any results for:
Make sure your spelling is correct or try broadening your search.
OptiNose Inc is a US-based specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. The lead product of the company, XHANCE nasal spray, utilizes a proprietary breath powered exhalation ... OptiNose Inc is a US-based specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. The lead product of the company, XHANCE nasal spray, utilizes a proprietary breath powered exhalation delivery system, to deliver a topically acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids. The pipeline products of the company include XHANCE, OPN-300, OPN-021, and AVP-825. Show more
YARDLEY, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today...
ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps Clinical...
PDUFA target action date is March 16, 2024, for the Company's sNDA. If approved, the Company is prepared for launch of XHANCE for treatment of patients diagnosed with chronic sinusitis Physicians...
YARDLEY, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.2223 | -18.6806722689 | 1.19 | 1.19 | 0.855 | 657486 | 0.99117689 | CS |
4 | -0.5523 | -36.3355263158 | 1.52 | 1.57 | 0.855 | 487292 | 1.20847007 | CS |
12 | -0.4523 | -31.8521126761 | 1.42 | 2.1 | 0.855 | 634782 | 1.57687226 | CS |
26 | -0.1023 | -9.56074766355 | 1.07 | 2.1 | 0.855 | 457289 | 1.46305392 | CS |
52 | -0.8923 | -47.9731182796 | 1.86 | 2.1 | 0.855 | 472214 | 1.35030513 | CS |
156 | -2.7423 | -73.9164420485 | 3.71 | 4.3 | 0.855 | 339938 | 1.9691842 | CS |
260 | -9.1123 | -90.3998015873 | 10.08 | 11.66 | 0.855 | 345537 | 3.44216571 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions